Literature DB >> 2446487

Medical management of malignant pericardial effusion by tetracycline sclerosis.

F A Shepherd1, C Morgan, W K Evans, J F Ginsberg, D Watt, K Murphy.   

Abstract

Fifty-eight patients with malignant pericardial effusion were seen from 1979 to 1986. A Kifa catheter was inserted into the pericardial sac and allowed to drain for 12 to 24 hours during electrocardiographic monitoring. Lidocaine hydrochloride, 100 mg, was instilled intrapericardially, followed by tetracycline hydrochloride, 500 to 1,000 mg, in 20 ml of normal saline solution. The catheter was clamped for 1 to 2 hours and then reopened. This procedure was repeated daily until the net drainage was less than 25 ml/24 hours. There were 22 male and 36 female patients (median age 58 years). The primary malignancy included lung (27 patients), breast (16 patients), stomach (3 patients), adenocarcinoma of unknown primary (7 patients), mesothelioma (2 patients) and chronic granulocytic leukemia, ovary and lymphoma (1 patient each). Fifty-six patients received 1 to 5 tetracycline instillations. In 1 patient, the catheter could not be inserted and in another, clotting occurred within the catheter before injection of tetracycline. Complications included transient atrial arrhythmias (5 patients), pain after injection (9 patients) and temperature higher than 37.5 degrees C (5 patients). One patient had a cardiac arrest during pericardiocentesis. Forty-three patients (74%) had control of their effusions for longer than 30 days (median survival 168 days, range 30 to 1,149+), and 5 patients (9%) died before 30 days without effusion. Eight patients (14%) did not achieve control. One declined further therapy after 1 instillation, and 3 died within 6 days with progressive malignancy. One patient had persistent drainage after 3 instillations, and 3 had reaccumulation of fluid 2, 6 and 27 days after catheter removal.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446487     DOI: 10.1016/0002-9149(87)90411-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  Pericardial Effusion and Tamponade.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-06

2.  Malignant pericardial effusion.

Authors:  J P Lewis
Journal:  West J Med       Date:  1989-02

3.  Pericardial effusion in patients with cancer: outcome with contemporary management strategies.

Authors:  R J Laham; D J Cohen; R E Kuntz; D S Baim; B H Lorell; M Simons
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

Review 4.  Modern approaches and use of surgical treatment for pericardial disease.

Authors:  Edward P Chen; Joseph I Miller
Journal:  Curr Cardiol Rep       Date:  2002-01       Impact factor: 2.931

5.  Thoracoscopic pericardial fenestration: diagnostic and therapeutic aspects.

Authors:  A Cantó; R Guijarro; A Arnau; A Fernández-Centeno; M A Císcar; J Galbis; A García-Vilanova
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

Review 6.  Managing malignant pericardial effusion.

Authors:  A C Buzaid; H S Garewal; B R Greenberg
Journal:  West J Med       Date:  1989-02

7.  Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion.

Authors:  W Tomkowski; M Szturmowicz; A Fijalkowska; S Filipecki; E Figura-Chojak
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 8.  Palliative treatment of malignant pericardial effusion: report of two cases and a review of the literature.

Authors:  A Sharma; R Kamble; L Kumar; B Bhargava; B M Biswal; V Kochupillai
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

9.  Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade.

Authors:  Witold Zbyszek Tomkowski; Joanna Wiśniewska; Monika Szturmowicz; Paweł Kuca; Janusz Burakowski; Jarosław Kober; Anna Fijałkowska
Journal:  Support Care Cancer       Date:  2003-09-23       Impact factor: 3.603

10.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.